Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Combined application of ciprofloxacin and tobramycin on mutant selective windows of ciprofloxacin against Pseudomonas aeruginosa].

Zhonghua yi xue za zhi - 31 May 2011

Liu Ming-tao, Sheng Mei-yan, Zhang Yun, Li Yu

Abstract excerpt

OBJECTIVE: To observe whether the mutant selective windows (MSW) of ciprofloxacin would be reduced after its combination against Pseudomonas aeruginosa in rabbits. METHODS: Firstly the minimal inhibitory concentration (MIC), mutant prevention concentration (MPC), mutant selective windows (MSW, MPC-MIC) and selective indices (SI, MPC/MIC) of ciprofloxacin and tobramycin were measured in vitro respectively with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Ciprofloxacin
Share to Drug Resistance, Bacterial

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug Therapy, Combination

Share to Microbial Sensitivity Tests

Share to Pseudomonas aeruginosa

Share to Pseudomonas Infections

Share to Rabbits

Share to Tobramycin

Source

Identifiers

PMID: 21756818

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Combined application of ciprofloxacin and tobramycin on mutant selective windows of ciprofloxacin against Pseudomonas aeruginosa].PMID 21756818Read ↗

[Mutant prevention concentrations of antibacterial agents to ocular pathogenic bacteria].Semantic proximity Read ↗

[Mutant prevention concentrations of fluoroquinolones for Staphylococcus aureus].Semantic proximity Read ↗

[Study investigating the activity of several fluoroquinolones against Pseudomonas aeruginosa using the mutant prevention concentration].Semantic proximity Read ↗

Pharmacokinetic/pharmacodynamic model-based combination therapy approach to target antibiotic resistant populations emerged from ciprofloxacin exposure.Semantic proximity Read ↗

Validation of the mutant selection window hypothesis with fosfomycin against Escherichia coli and Pseudomonas aeruginosa: an in vitro and in vivo comparative study.Semantic proximity Read ↗

Bacterial resistance studies using in vitro dynamic models: the predictive power of the mutant prevention and minimum inhibitory antibiotic concentrations.Semantic proximity Read ↗

In vivo pharmacodynamic efficacy of gatifloxacin against Streptococcus pneumoniae in an experimental model of pneumonia: impact of the low levels of fluoroquinolone resistance on the enrichment of resistant mutants.Semantic proximity Read ↗

In vivo evaluation of mutant selection window of cefquinome against Escherichia coli in piglet tissue-cage model.Semantic proximity Read ↗

[The concentrations of fluoroquinolones in prevention of Staphylococcus epidermidis from mutant in ocular surface].Semantic proximity Read ↗

Mutant prevention concentration of ciprofloxacin and enrofloxacin against Escherichia coli, Salmonella Typhimurium and Pseudomonas aeruginosa.Semantic proximity Read ↗

[Development of multi-drug resistant mutants of clinical isolates of Pseudomonas aeruginosa after exposure to fluoroquinolone].Semantic proximity Read ↗

Testing the mutant selection window hypothesis in vitro and in vivo with Staphylococcus aureus exposed to fosfomycin.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.